Health Care & Life Sciences » Pharmaceuticals | Paratek Pharmaceuticals Inc.

Paratek Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
70,245.00
95,856.00
133,745.00
128,855.00
151,885.00
250,617
Total Accounts Receivable
2,923.00
4,434.00
745.00
323.00
5,889.00
249
Other Current Assets
459.00
1,039.00
7,927.00
2,922.00
2,712.00
4,377
Total Current Assets
73,627.00
101,329.00
142,417.00
132,100.00
160,486.00
255,243
Net Property, Plant & Equipment
43.00
49.00
779.00
1,188.00
1,711.00
1,173
Total Investments and Advances
-
2,946.00
250.00
250.00
250.00
42,736
Intangible Assets
-
5,643.00
2,178.00
1,844.00
971.00
829
Other Assets
-
-
294.00
350.00
280.00
211
Total Assets
73,670.00
109,967.00
145,918.00
135,732.00
163,698.00
300,192
Accounts Payable
413.00
489.00
-
4,418.00
3,555.00
Income Tax Payable
36.00
-
-
-
-
Other Current Liabilities
1,479.00
3,252.00
20,502.00
15,994.00
13,234.00
Total Current Liabilities
1,928.00
3,741.00
20,502.00
20,412.00
16,789.00
Long-Term Debt
-
-
19,565.00
38,974.00
59,186.00
Provision for Risks & Charges
-
2,850.00
1,000.00
655.00
71.00
Other Liabilities
-
8,152.00
3,611.00
4,099.00
5,174.00
Total Liabilities
1,928.00
14,743.00
44,678.00
64,140.00
81,220.00
Common Equity (Total)
71,742.00
95,224.00
101,240.00
71,592.00
82,478.00
Total Shareholders' Equity
71,742.00
95,224.00
101,240.00
71,592.00
82,478.00
Total Equity
71,742.00
95,224.00
101,240.00
71,592.00
82,478.00
Liabilities & Shareholders' Equity
73,670.00
109,967.00
145,918.00
135,732.00
163,698.00

About Paratek Pharmaceuticals

View Profile
Address
75 Park Plaza
Boston Massachusetts 02116
United States
Employees -
Website http://www.paratekpharma.com
Updated 07/08/2019
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include Omadacycline and Sarecycline, which are used for the treatment of serious community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, and urinary tract infections. The company was founded in February 2001 and is headquartered in Boston, MA.